These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

282 related items for PubMed ID: 27888800

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Clinical Impact of KRAS and GNAS Analysis Added to CEA and Cytology in Pancreatic Cystic Fluid Obtained by EUS-FNA.
    Faias S, Duarte M, Albuquerque C, da Silva JP, Fonseca R, Roque R, Dias Pereira A, Chaves P, Cravo M.
    Dig Dis Sci; 2018 Sep; 63(9):2351-2361. PubMed ID: 29796909
    [Abstract] [Full Text] [Related]

  • 4. Molecular Genetic Analysis of Ovarian Brenner Tumors and Associated Mucinous Epithelial Neoplasms: High Variant Concordance and Identification of Mutually Exclusive RAS Driver Mutations and MYC Amplification.
    Tafe LJ, Muller KE, Ananda G, Mitchell T, Spotlow V, Patterson SE, Tsongalis GJ, Mockus SM.
    Am J Pathol; 2016 Mar; 186(3):671-7. PubMed ID: 26797085
    [Abstract] [Full Text] [Related]

  • 5. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
    Wu RC, Chen SJ, Chen HC, Tan KT, Jung SM, Lin CY, Chao AS, Huang KG, Chou HH, Chang TC, Chao A, Lai CH.
    Mod Pathol; 2020 Dec; 33(12):2534-2543. PubMed ID: 32616873
    [Abstract] [Full Text] [Related]

  • 6. Targeted deep sequencing of mucinous ovarian tumors reveals multiple overlapping RAS-pathway activating mutations in borderline and cancerous neoplasms.
    Mackenzie R, Kommoss S, Winterhoff BJ, Kipp BR, Garcia JJ, Voss J, Halling K, Karnezis A, Senz J, Yang W, Prigge ES, Reuschenbach M, Doeberitz MV, Gilks BC, Huntsman DG, Bakkum-Gamez J, McAlpine JN, Anglesio MS.
    BMC Cancer; 2015 May 19; 15():415. PubMed ID: 25986173
    [Abstract] [Full Text] [Related]

  • 7. Genetic analysis for mucinous ovarian carcinoma with infiltrative and expansile invasion and mucinous borderline tumor: a retrospective analysis.
    Hada T, Miyamoto M, Ohtsuka Y, Suminokura J, Ito T, Kishimoto N, Nishitani S, Takada M, Imauji A, Tanabe R, Takano M.
    Diagn Pathol; 2023 Apr 20; 18(1):49. PubMed ID: 37081552
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.
    Sieben NL, Macropoulos P, Roemen GM, Kolkman-Uljee SM, Jan Fleuren G, Houmadi R, Diss T, Warren B, Al Adnani M, De Goeij AP, Krausz T, Flanagan AM.
    J Pathol; 2004 Mar 20; 202(3):336-40. PubMed ID: 14991899
    [Abstract] [Full Text] [Related]

  • 10. [Molecular genetics of epithelial ovarian neoplasms: correlations with phenotype and biological behavior].
    Diebold J.
    Pathologe; 1998 Feb 20; 19(2):95-103. PubMed ID: 9556793
    [Abstract] [Full Text] [Related]

  • 11. The molecular pathology of ovarian serous borderline tumors.
    Malpica A, Wong KK.
    Ann Oncol; 2016 Apr 20; 27 Suppl 1(Suppl 1):i16-i19. PubMed ID: 27141064
    [Abstract] [Full Text] [Related]

  • 12. KRAS mutation testing in borderline ovarian tumors and low-grade ovarian carcinomas with a rapid, fully integrated molecular diagnostic system.
    Sadlecki P, Antosik P, Grzanka D, Grabiec M, Walentowicz-Sadlecka M.
    Tumour Biol; 2017 Oct 20; 39(10):1010428317733984. PubMed ID: 28992761
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. P53, MAPK, topoisomerase II alpha and Ki67 immunohistochemical expression and KRAS/BRAF mutation in ovarian serous carcinomas.
    Sundov D, Caric A, Mrklic I, Gugic D, Capkun V, Hofman ID, Mise BP, Tomic S.
    Diagn Pathol; 2013 Feb 06; 8():21. PubMed ID: 23388101
    [Abstract] [Full Text] [Related]

  • 15. KRAS mutation positive mucinous adenocarcinoma originating in mature ovarian teratoma: case report and review of literature.
    Hershkovitz D, Vlodavsky E, Simon E, Ben-Izhak O.
    Pathol Int; 2013 Dec 06; 63(12):611-4. PubMed ID: 24422958
    [Abstract] [Full Text] [Related]

  • 16. Ovarian mucinous tumor with malignant mural nodules: dedifferentiation or collision?
    Desouki MM, Khabele D, Crispens MA, Fadare O.
    Int J Gynecol Pathol; 2015 Jan 06; 34(1):19-24. PubMed ID: 25473748
    [Abstract] [Full Text] [Related]

  • 17. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants.
    Mayr D, Hirschmann A, Löhrs U, Diebold J.
    Gynecol Oncol; 2006 Dec 06; 103(3):883-7. PubMed ID: 16806438
    [Abstract] [Full Text] [Related]

  • 18. The status of Her2 amplification and Kras mutations in mucinous ovarian carcinoma.
    Chang KL, Lee MY, Chao WR, Han CP.
    Hum Genomics; 2016 Dec 28; 10(1):40. PubMed ID: 28031051
    [Abstract] [Full Text] [Related]

  • 19. RAS Mutation in Mucinous Carcinoma of the Ovary.
    Panyavaranant P, Teerapakpinyo C, Pohthipornthawat N, Oranratanaphan S, Shuangshoti S, Triratanachat S.
    Asian Pac J Cancer Prev; 2019 Apr 29; 20(4):1127-1132. PubMed ID: 31030485
    [Abstract] [Full Text] [Related]

  • 20. Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma.
    Gemignani ML, Schlaerth AC, Bogomolniy F, Barakat RR, Lin O, Soslow R, Venkatraman E, Boyd J.
    Gynecol Oncol; 2003 Aug 29; 90(2):378-81. PubMed ID: 12893203
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.